Esmat Mustafa, MD
Nephrology · Phoenix, AZNPI 1033307574
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 316 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AstraZeneca at 25.8% of the total. 2025 is the largest year on record at $1,957, 2.9 times the $674 reported in 2019. Among nephrology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Otsuka America Pharmaceutical, Inc.$877
- Mallinckrodt Hospital Products Inc.$628
- Bayer$628
- Amgen$472
- Johnson & Johnson$444
- plus $2K from 25 others
Across 6 payments — averaging $2231.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$12K
- Akebia Therapeutics Inc$2K
What the payments were for
- Speaking & faculty fees$2003%
- Food & beverage$7,06996%
- Education$1232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 76 | $1,907 |
| Otsuka America Pharmaceutical, Inc. | 41 | $877 |
| Mallinckrodt Hospital Products Inc. | 25 | $628 |
| Bayer | 28 | $628 |
| Amgen(2 entities) | 24 | $472 |
| Johnson & Johnson | 22 | $444 |
| Travere Therapeutics, Inc. | 15 | $329 |
| Vifor Pharma, Inc. | 6 | $304 |
| Alnylam Pharmaceuticals Inc. | 7 | $271 |
| ANI Pharmaceuticals, Inc. | 14 | $252 |
| Daiichi Sankyo Inc. | 8 | $246 |
| Akebia Therapeutics Inc | 6 | $113 |
| Novartis | 5 | $99 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $97 |
| Fresenius USA Marketing, Inc. | 5 | $95 |
| Ardelyx, Inc. | 5 | $85 |
| Calliditas Therapeutics US Inc. | 4 | $78 |
| Genentech USA, Inc. | 3 | $59 |
| Aurinia Pharma U.S., Inc. | 3 | $54 |
| Astellas Pharma US Inc | 2 | $51 |
| Shield Therapeutics Inc | 2 | $42 |
| GSK | 2 | $41 |
| Boehringer Ingelheim | 2 | $40 |
| OPKO Pharmaceuticals, LLC | 2 | $40 |
| Novo Nordisk | 2 | $34 |
| Veloxis Pharmaceuticals, Inc. | 1 | $26 |
| Boston Scientific | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Sanofi | 1 | $16 |
| Medtronic | 1 | $16 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,391 in reported general payments places this provider in the 90th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 99 | $84,293 |
| KerendiaFinerenone | 38 | $37,605 |
| VelphoroSucroferric Oxyhydroxide | 17 | $34,125 |
| LokelmaSodium Zirconium Cyclosilicate | 37 | $29,713 |
| VeltassaPatiromer Calcium Sorbitex | 19 | $18,453 |
| Lanthanum Carbonate | 15 | $13,749 |
| Sevelamer Carbonate | 43 | $6,968 |
| DapagliflozinDapagliflozin Propanediol | 12 | $5,780 |
| Olmesartan Medoxomil | 128 | $3,992 |
| Bumetanide | 103 | $3,701 |
| Nifedipine ErNifedipine | 52 | $2,026 |
| Fluconazole | 20 | $1,414 |
| Potassium Chloride | 48 | $1,107 |
| Midodrine Hcl | 16 | $1,028 |
| Carvedilol | 91 | $736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,907 | $114,006136 claims |
| BayerKerendia | $628 | $37,60538 claims |
| Fresenius USA Marketing, Inc.Velphoro | $95 | $34,12517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 259 nephrology providers in Arizona.
Other nephrology in Phoenix
- Samer Bani HaniPhoenix$54K
- Leslie ThomasPhoenix$22K
- Alexander NimriPhoenix$21K
- Edgardo LaurelPhoenix$15K
- Sharareh SaadatPhoenix$15K
- Amar BistaPhoenix$12K
- Maher MousaPhoenix$9K
- Paul SacksPhoenix$8K
- William WeissPhoenix$8K
- Hui ZhaoPhoenix$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.